Otsuka Pharmaceutical Patent-Cliff Exposure & CMS Drug Spending Portfolio

Otsuka Pharmaceutical (Rockville, MD): 10 reconciled FDA prescription therapies (94.9% 2025 to 2030 cliff risk), $3.46B 2024 CMS Part D & Medicaid spend, and 96 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterRockville, MD
Reconciled FDA Portfolio Therapies10
2025 to 2030 Patent-Cliff Revenue Exposure94.9%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$3.46B
2024 Medicare Part D Spend$1.86B
2024 Medicaid Spend$1.60B
California HCAI SB 17 Filings96 WAC filings (max 481.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.